3 Reasons I Bought Novo Nordisk Stock Instead of Eli Lilly

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are two phenomenal growth stocks that investors probably can't go wrong with when investing in for the long term. They are leaders in the GLP-1 weight loss space, and have been generating strong growth in recent years.But while they are similar, the stock I invested in earlier this year was Novo Nordisk. Here's why I bought it instead of its larger rival, and why I still think Novo is the better buy right now.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool